Back to Archived News
Ulysses Pharma Receives First Issued Patent on Novel Class of Antibiotics
Tuesday, August 12, 2008
Sherbrooke, Quebec -- Ulysses Pharma today announced the issuance of US Patent 7,410,974, covering its novel class of antibiotics which target drug resistant bacteria. The FQN class of antibiotics are designed to make the development of resistance almost impossible, because of their exquisite potency, rapid killing of bacteria and multiple mechanisms of action. This is the first in a series of patents covering the company’s technology to combat drug resistant bacteria.
"This first patent secures the intellectual property on our approach to treat resistant bacteria, using new chemistry against an established antibacterial target", commented Roger Léger, VP R&D Chemistry. "We believe this technology holds promise for the treatment of both Gram positive and Gram negative bacterial infections."
In 2006, the Centers for Disease Control (CDC) recorded some 19,000 deaths from methicillin resistant Staphylococcus aureus (MRSA) infections, a Gram positive resistant bacterial infection. On the Gram negative side, which includes difficult to treat pathogens such as Pseudomonas and Klebsiella, morbidity and mortality are increasing at a rapid pace across North America and the world, with very limited treatment options.
About Ulysses Pharma
Ulysses Pharma is a privately held biopharmaceutical company based in Sherbrooke, Canada engaged in the research and development of new antibiotics to treat severe human infections caused by drug resistant bacteria. For additional information please visit the company’s web site at www.ulyssespharma.com.
Back to Archived News
